-- First quarter 2021 net revenues of $54.5 million; net income of $0.1 million and diluted earnings per share of $0.01 --
-- First quarter adjusted non-GAAP EBITDA of $18.9 million and adjusted non-GAAP diluted earnings per share of $1.04 --
-- Cortrophin® Gel sNDA re-filing on track for Q2 2021 submission --
-- Strengthened R&D engine and enhanced generics and CDMO business through pending acquisition of Novitium Pharma--
-- Expanded branded products portfolio through April 1 acquisition of Sandoz Inc. NDAs --
ANI Pharmaceuticals management will host its first quarter 2021 conference call as follows:
Date | Friday, May 7, 2021 | ||
Time | 8:30 a.m. ET | ||
Toll free (U.S.) | (866) 518-6930 | ||
Webcast (live and replay) | www.anipharmaceuticals.com, under the "Investors" section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for one week by dialing 800-934-5153 and entering access code 5412658.
https://finance.yahoo.com/news/ani-pharmaceuticals-reports-first-quarter-105000609.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.